Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988

被引:38
作者
Reed, E
Zerbe, CS
Brawley, OW
Bicher, A
Steinberg, SM
机构
[1] NCI, Med Branch, Bethesda, MD 20892 USA
[2] NCI, Div Canc Prevent & Control, Bethesda, MD 20892 USA
[3] NCI, Biostat & Data Management Branch, Div Clin Sci, Bethesda, MD 20892 USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2000年 / 23卷 / 02期
关键词
ovarian cancer; autopsy; cisplatin;
D O I
10.1097/00000421-200004000-00002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Between 1972 and 1988, more than 500 women were treated for ovarian cancer at the National Cancer Institute in Bethesda, Maryland on approved experimental treatment protocols. Of these, 73 underwent autopsy evaluation on the National Cancer Institute campus. We have analyzed the autopsy reports of those individuals to determine the patterns of disease spread at death. By comparison with the literature, the demographics of the cohort did not differ from previously published reports, other than the extent of chemotherapy received antemortem. Median survival of the cohort was 15.6 months (range, 1.7-108.3 months), and median age at diagnosis was 55 years (range, 24-74 years). The median number of treatments regimens received was two (range, 1-6). The pattern of disease spread at autopsy was different from that in previously published work in that there was a higher proportion of patients with disease found in liver parenchyma, lung pleura, and the pericardium. Patients who received cisplatin as part of their initial treatment regimen had a higher incidence of metastases to the adrenal glands, thoracic nodes, bladder, and liver parenchyma, which was not explained by differences in survival. Median survival for patients who received cisplatin as part of their initial therapy was 15.6 months, compared with a median of 15.4 months for patients who did not, These data suggest a changing pattern of disease spread in patients with ovarian cancer receiving aggressive chemotherapy. This may be caused by some effect of platinum-based therapy on the metastatic potential of the tumor.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 25 条
[1]  
BASSETT WB, 1986, J CLIN ONCOL, V4, P614
[2]  
Bergman AM, 1996, CLIN CANCER RES, V2, P521
[4]   A PRELIMINARY RISK-BENEFIT ASSESSMENT OF PACLITAXEL [J].
BITTON, RJ ;
FIGG, WD ;
REED, E .
DRUG SAFETY, 1995, 12 (03) :196-208
[5]  
Dabholkar M, 1993, Cancer Chemother Biol Response Modif, V14, P86
[6]   DISTRIBUTION OF DISEASE AT AUTOPSY IN 100 WOMEN WITH OVARIAN-CANCER [J].
DVORETSKY, PM ;
RICHARDS, KA ;
ANGEL, C ;
RABINOWITZ, L ;
STOLER, MH ;
BEECHAM, JB ;
BONFIGLIO, TA .
HUMAN PATHOLOGY, 1988, 19 (01) :57-63
[7]   ENHANCED MALIGNANT CONVERSION OF BENIGN MOUSE SKIN TUMORS BY CISPLATIN [J].
HENNINGS, H ;
SHORES, RA ;
POIRIER, MC ;
REED, E ;
TARONE, RE ;
YUSPA, SH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (10) :836-840
[8]  
JULIAN CG, 1974, OBSTET GYNECOL, V44, P873
[9]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[10]  
Kataoka A, 1994, Nihon Sanka Fujinka Gakkai Zasshi, V46, P337